UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms

The Journal of experimental medicine, 2015-10, Vol.212 (11), p.1833-1850

2015

Link zum Volltext

Verfügbarkeit prüfen

MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system

PloS one, 2014-12, Vol.9 (12), p.e114398-e114398

2014

Link zum Volltext

Verfügbarkeit prüfen

Effects of High- and Low-LET Radiation on Human Hematopoietic System Reconstituted in Immunodeficient Mice

Radiation research, 2019-02, Vol.191 (2), p.162

2019

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Blood advances, 2021-02, Vol.5 (4), p.1092-1096

2021

Link zum Volltext

Verfügbarkeit prüfen

The genetic landscape of dural marginal zone lymphomas

Oncotarget, 2016-07, Vol.7 (28), p.43052-43061

2016

Link zum Volltext

Verfügbarkeit prüfen

Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation

Human pathology, 2012-11, Vol.43 (11), p.1828-1838

2012

Link zum Volltext

Verfügbarkeit prüfen

Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study

Blood, 2013-11, Vol.122 (21), p.4333-4333

2013

Link zum Volltext

Verfügbarkeit prüfen

Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia

Human pathology, 2012-12, Vol.43 (12), p.2354-2359

2012

Link zum Volltext

Verfügbarkeit prüfen

Commentary on "Small cell lung cancer: time to diagnosis and treatment"

Southern medical journal (Birmingham, Ala.), 2012-08, Vol.105 (8), p.424

Hoehn, Daniela

2012

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4595-TPS4595

2021

Link zum Volltext

Verfügbarkeit prüfen

Laparoscopic Management of Peritoneal Mesothelioma Associated with Pelvic Endometriosis

Journal of minimally invasive gynecology, 2010-09, Vol.17 (5), p.646-650

2010

Link zum Volltext

Verfügbarkeit prüfen

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

Clinical cancer research, 2015-10, Vol.21 (20), p.4663-4675

2015

Link zum Volltext

Verfügbarkeit prüfen

The Effect of High LET Space Radiation on the Human Hematopoietic System: Preliminary Results from the First In Vivo Model

Blood, 2015-12, Vol.126 (23), p.5416-5416

2015

Link zum Volltext

Verfügbarkeit prüfen

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Blood, 2017-12, Vol.130, p.5600-5600

2017

Link zum Volltext

Verfügbarkeit prüfen

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Blood, 2017-12, Vol.130, p.4714-4714

2017

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Blood, 2020-11, Vol.136 (Supplement 1), p.48-49

2020

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Leukemia & lymphoma, 2022-08, Vol.63 (10), p.2383-2392

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Blood, 2018-11, Vol.132 (Supplement 1), p.151-151

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases

The American journal of surgical pathology, 2016-05, Vol.40 (5), p.676-688

2016

Link zum Volltext

Verfügbarkeit prüfen

Flow Cytometry of Body Fluid Specimens: Diagnostic Value and Clinical Utility in Patients With or Without Prior Hematologic Malignancy

American journal of clinical pathology, 2017-03, Vol.147 (suppl_2), p.S178-S179

2017

Link zum Volltext

Verfügbarkeit prüfen

Results from the Epcore NHL-2 Trial Arm 8: Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S357-S358

2024

Link zum Volltext

Verfügbarkeit prüfen

C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?

Leukemia research, 2014-09, Vol.38 (9), p.1061-1066

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(72)
Buchkapitel
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms

Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene

MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system

Effects of High- and Low-LET Radiation on Human Hematopoietic System Reconstituted in Immunodeficient Mice

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

The genetic landscape of dural marginal zone lymphomas

Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation

Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study

Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study

Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia

Commentary on "Small cell lung cancer: time to diagnosis and treatment"

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)

Laparoscopic Management of Peritoneal Mesothelioma Associated with Pelvic Endometriosis

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

The Effect of High LET Space Radiation on the Human Hematopoietic System: Preliminary Results from the First In Vivo Model

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases

Flow Cytometry of Body Fluid Specimens: Diagnostic Value and Clinical Utility in Patients With or Without Prior Hematologic Malignancy

Results from the Epcore NHL-2 Trial Arm 8: Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP

C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?

Suchergebnisse filtern